HER2 amplification is clinically observed in approximately 20 to 30% of breast cancer patients, and plays a key role in the tumorigenesis, metastasis and chemotherapy resistance in HER2-positive breast cancer [1]. The gene discussed is ERBB2; the disease is breast carcinoma.